Articles tagged with "U.S. Food and Drug Administration (FDA)"

Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia

December 12, 2022 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Ustekinumab for Children with PsA

November 7, 2022 • By Michele B. Kaufman, PharmD, BCGP

Belimumab Promising for Children with Lupus Nephritis

October 6, 2022 • By Michele B. Kaufman, PharmD, BCGP

An Evidence-Based Drug Update & Guidance for Rheumatologists

August 14, 2022 • By Samantha C. Shapiro, MD

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

July 13, 2022 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Risankizumab-rzaa for PsA

April 20, 2022 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA

February 2, 2022 • By Michele B. Kaufman, PharmD, BCGP

FDA Authorizes New Long-Acting, Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

December 13, 2021 • By U.S. Food & Drug Administration

The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

November 23, 2021 • By Jason Liebowitz, MD

Considerations for Prescribing Avacopan for ANCA-Associated Vasculitis

October 27, 2021 • By Michele B. Kaufman, PharmD, BCGP

1
2
3
…
12
Next Page »